NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis $1.42 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.42 0.00 (-0.35%) As of 04/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Geron Stock (NASDAQ:GERN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Geron alerts:Sign Up Key Stats Today's Range$1.36▼$1.4450-Day Range$1.24▼$2.6252-Week Range$1.17▼$5.34Volume6.36 million shsAverage Volume11.49 million shsMarket Capitalization$904.42 millionP/E RatioN/ADividend YieldN/APrice Target$5.75Consensus RatingModerate Buy Company OverviewGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More… Geron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreGERN MarketRank™: Geron scored higher than 77% of companies evaluated by MarketBeat, and ranked 140th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGeron has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Geron's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.25) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.22% of the float of Geron has been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Geron has recently increased by 31.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Sustainability and ESG1.3 / 5Environmental Score-2.76 Percentage of Shares Shorted10.22% of the float of Geron has been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Geron has recently increased by 31.25%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.30 News SentimentGeron has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 45 news articles for Geron this week, compared to 10 articles on an average week.Search InterestOnly 14 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -72% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Geron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,150.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers – GERNApril 25 at 10:55 AM | globenewswire.comInvestors who lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class Action - GERNApril 25 at 5:45 AM | prnewswire.comWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsApril 26, 2025 | True Market Insiders (Ad)Leerink Partnrs Predicts Geron's Q2 Earnings (NASDAQ:GERN)April 25 at 3:11 AM | americanbankingnews.comROSEN, A LEADING NATIONAL FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERNApril 24 at 1:49 PM | globenewswire.comGeron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights – GERNApril 24 at 12:27 PM | globenewswire.comThe Gross Law Firm Reminds Geron Corporation Investors of the Pending Class Action Lawsuit with ...April 24 at 6:41 AM | gurufocus.comThe Gross Law Firm Reminds Geron Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERNApril 24 at 5:45 AM | prnewswire.comSee More Headlines GERN Stock Analysis - Frequently Asked Questions How have GERN shares performed this year? Geron's stock was trading at $3.54 at the beginning of 2025. Since then, GERN shares have decreased by 59.9% and is now trading at $1.42. View the best growth stocks for 2025 here. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) issued its quarterly earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.04). The biopharmaceutical company earned $47.54 million during the quarter, compared to analysts' expectations of $45.29 million. Geron had a negative trailing twelve-month return on equity of 67.53% and a negative net margin of 682.48%. Read the conference call transcript. Who are Geron's major shareholders? Geron's top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.06%), Moody National Bank Trust Division (0.05%), Cambridge Investment Research Advisors Inc. (0.03%) and Lazari Capital Management Inc. (0.01%). Insiders that own company stock include Olivia Kyusuk Bloom, Scott Alan Samuels, John A Scarlett, Elizabeth G O'farrell, Susan Molineaux, V Bryan Lawlis, Faye Feller and Andrew J Grethlein. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings2/26/2025Today4/26/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$5.75 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+304.9%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-682.48% Pretax Margin-682.47% Return on Equity-67.53% Return on Assets-45.46% Debt Debt-to-Equity Ratio0.04 Current Ratio2.89 Quick Ratio2.74 Sales & Book Value Annual Sales$76.99 million Price / Sales11.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book3.09Miscellaneous Outstanding Shares636,913,000Free Float585,761,000Market Cap$904.42 million OptionableOptionable Beta0.66 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:GERN) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.